Item 2.02 Results of Operations and Financial Condition. On January 9, 2023, Moderna, Inc. (the "Company") issued a press release (the "Press Release") in connection with the Company's presentation on the same date at the 41st Annual J.P. Morgan Healthcare Conference. The Press Release contains certain preliminary financial information as of and for the fiscal year ended December 31, 2022. Specifically, the Press Release states that for the fiscal year ended December 31, 2022, the Company (i) generated approximately $18.4 billion in product sales (unaudited) from sales of its COVID-19 vaccine and (ii) incurred approximately $3.3 billion in research and development expenses (unaudited). The Press Release also states the Company's current expectation with respect to its cash, cash equivalents and investments in marketable securities (unaudited) as of December 31, 2022 of over $18 billion.

The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's results of operations for the fiscal year ended December 31, 2022 or financial condition as of December 31, 2022. The audit of the Company's financial statements for the year ended December 31, 2022 is ongoing and could result in changes to the information in this Item 2.02.

Item 7.01 Regulation FD Disclosure.

The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01.

The information contained in Items 2.02 and 7.01, as well as Exhibit 99.1, to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit
     No.             Description
    99.1               Press release by Moderna, Inc. dated January 9, 2023
     104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses